Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Pathology

Diagnosis & Understanding Your Pathology Report

At a Glance

Diagnosing AL amyloidosis requires finding amyloid in a tissue biopsy using a Congo Red stain, then confirming it is the 'AL' type using mass spectrometry. Doctors also rely on a blood and urine 'triple-test' to measure abnormal light chain proteins and track your response to treatment.

Diagnosing AL amyloidosis is a two-step process: first, doctors must prove that amyloid is present in your body; second, they must prove that it is made of light chains (the “AL” type) and not some other protein [1][2]. Because this disease is rare and complex, a “completeness checklist” of tests is essential for an accurate diagnosis and treatment plan [3].

The Blood and Urine “Triple-Test”

To find the source of the amyloid, doctors look for monoclonal proteins (abnormal proteins produced by a single “clone” of plasma cells) [4]. A single test is rarely enough. Instead, specialists use a combination of three tests that, together, identify the abnormal protein in approximately 99% of patients [5][6]:

  1. sFLC (Serum Free Light Chain Assay): Measures the amount of “free” light chains in your blood [4]. The most important number is the dFLC—the difference between your “involved” (bad) and “uninvolved” (good) light chains [7].
  2. sIFE (Serum Immunofixation): A highly sensitive way to identify the specific type of monoclonal protein in your blood [8].
  3. uIFE (Urine Immunofixation): Similar to the blood test, this checks your urine for light chains (historically called “Bence-Jones proteins”) [8].

Biopsy: Finding the Fibrils

A biopsy is the only way to definitively see the amyloid fibrils [1]. Pathologists use a special dye called Congo Red. When viewed under a polarized microscope, amyloid stained with Congo Red glows with a characteristic “apple-green birefringence” [1][9].

  • Abdominal Fat Pad Aspiration: A minimally invasive “surrogate” biopsy where a small amount of fat is taken from the belly [10]. It has a sensitivity of about 73–79% [11].
  • Bone Marrow Biopsy: Used to find the “clone” of plasma cells causing the disease [12]. Its sensitivity for finding amyloid is lower (50–60%), but it is essential for understanding the underlying bone marrow disorder [11][13].
  • Involved Organ Biopsy: If fat pad and bone marrow tests are negative but suspicion is high, doctors may biopsy the affected organ (heart, kidney, or liver) [14]. These have a diagnostic sensitivity of nearly 100% but are more invasive [15][9].

Mass Spectrometry: The Gold Standard

Once amyloid is found, it must be “typed.” Historically, laboratories used Immunohistochemistry (IHC), which uses antibodies to tag the protein [16]. However, IHC can be inconsistent or produce “background noise” that leads to misdiagnosis [17][18].

Mass Spectrometry (LC-MS/MS) is now considered the gold standard [19]. It breaks the amyloid down into its individual protein components and identifies them with 100% accuracy [16][17]. This is critical because treating AL amyloidosis with the wrong drugs (like those meant for ATTR) can be ineffective or harmful [20][21].

Pathology Report Checklist

Your diagnostic workup is not complete until you have:

  • [ ] Congo Red Stain result showing apple-green birefringence [1].
  • [ ] Amyloid Typing via Mass Spectrometry (preferred) or IHC [16].
  • [ ] Bone Marrow Analysis including plasma cell percentage [12].
  • [ ] Baseline Cardiac Markers (NT-proBNP and Troponin) for staging [22][23].
  • [ ] Baseline Kidney Markers (24-hour urine protein or protein/creatinine ratio) [24].

Common questions in this guide

What tests are used to diagnose AL amyloidosis?
Doctors use a blood and urine 'triple-test' to find abnormal light chain proteins in your body. They also perform biopsies of your fat pad, bone marrow, or an affected organ to confirm the physical presence of amyloid tissue.
What does a positive Congo Red stain mean on my pathology report?
A Congo Red stain is a special dye pathologists use on your biopsy sample. If amyloid is present in the tissue, the dye makes it glow with a characteristic apple-green color when viewed under a polarized microscope.
Why is mass spectrometry important for amyloid typing?
Mass spectrometry is the gold standard for identifying the exact type of amyloid protein with absolute accuracy. This ensures you receive the correct treatment, as AL amyloidosis requires completely different therapies than other types of amyloidosis.
What is an abdominal fat pad biopsy?
A fat pad aspiration is a minimally invasive procedure where a small amount of fat is taken from your belly. It is often the first biopsy doctors use to check for amyloid fibrils because it is much less invasive than biopsying your heart or kidney.
What does the dFLC number on my blood test mean?
The dFLC is the difference between the abnormal (involved) and normal (uninvolved) free light chains in your blood. Your care team tracks this specific number to measure how well your disease is responding to chemotherapy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Did my blood and urine tests include the 'triple-test' panel: sFLC, sIFE, and uIFE?
  2. 2.Was my tissue sample typed using Mass Spectrometry, or just Immunohistochemistry?
  3. 3.If my fat pad biopsy was negative, do we need to biopsy an involved organ like my heart or kidney?
  4. 4.What is my 'dFLC' number, and how will we use it to measure my response to chemotherapy?
  5. 5.Does my pathology report confirm 'apple-green birefringence' under a polarized microscope?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment.

    Gertz MA

    American journal of hematology 2024; (99(2)):309-324 doi:10.1002/ajh.27177.

    PMID: 38095141
  2. 2

    Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment.

    Zanwar S, Gertz MA, Muchtar E

    Journal of the National Comprehensive Cancer Network : JNCCN 2023; (21(1)):83-90 doi:10.6004/jnccn.2022.7077.

    PMID: 36630897
  3. 3

    Primary systemic amyloidosis: A brief overview.

    Hughes MS, Lentzsch S

    Presse medicale (Paris, France : 1983) 2025; (54(1)):104267 doi:10.1016/j.lpm.2024.104267.

    PMID: 39672504
  4. 4

    Evaluation of laboratory diagnostic tests for light-chain clonality and bone marrow findings in AL amyloidosis.

    Lee T, Park CJ, Kim M, et al.

    Blood research 2023; (58(1)):71-76 doi:10.5045/br.2023.2022232.

    PMID: 36987618
  5. 5

    A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing.

    Muchtar E, Gertz MA, Kyle RA, et al.

    Mayo Clinic proceedings 2019; (94(3)):472-483 doi:10.1016/j.mayocp.2018.08.006.

    PMID: 30770096
  6. 6

    [The diagnostic and prognostic values of serum free light chain in patients with primary light chain amyloidosis].

    Zhang CL, Feng J, Shen KN, et al.

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2016; (37(11)):942-945 doi:10.3760/cma.j.issn.0253-2727.2016.11.003.

    PMID: 27995877
  7. 7

    Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.

    Nguyen VP, Rosenberg A, Mendelson LM, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2018; (25(3)):156-159 doi:10.1080/13506129.2018.1490261.

    PMID: 30032640
  8. 8

    Serum Free Light Chain Assay and κ/λ Ratio Performance in Patients Without Monoclonal Gammopathies:  High False-Positive Rate.

    Singh G

    American journal of clinical pathology 2016; (146(2)):207-14 doi:10.1093/ajcp/aqw099.

    PMID: 27473738
  9. 9

    Light-chain cardiac amyloidosis for the non-expert: pearls and pitfalls.

    De Michieli L, Sinigiani G, De Gaspari M, et al.

    Internal and emergency medicine 2023; (18(7)):1879-1886 doi:10.1007/s11739-023-03335-3.

    PMID: 37338717
  10. 10

    Utility of abdominal skin plus subcutaneous fat and rectal mucosal biopsy in the diagnosis of AL amyloidosis with renal involvement.

    Li T, Huang X, Cheng S, et al.

    PloS one 2017; (12(9)):e0185078 doi:10.1371/journal.pone.0185078.

    PMID: 28926601
  11. 11

    Detection yield of surrogate tissue biopsies across amyloidosis classes: a large-scale analysis of 4,027 patients.

    Burke NJ, Mendelson LM, Joshi T, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2025; 1-9 doi:10.1080/13506129.2025.2606847.

    PMID: 41460224
  12. 12

    Unusual Case of Nephrotic Syndrome From Light Chain Amyloidosis in a 37-Year-Old Patient.

    Salameh OK, Darok MC, Kane JA, et al.

    Cureus 2021; (13(9)):e18120 doi:10.7759/cureus.18120.

    PMID: 34692330
  13. 13

    Abdominal subcutaneous fat pad aspiration and bone marrow examination for the diagnosis of AL amyloidosis: the reliability of immunohistochemistry.

    Miyazaki K, Kawai S, Suzuki K

    International journal of hematology 2015; (102(3)):289-95 doi:10.1007/s12185-015-1827-8.

    PMID: 26115876
  14. 14

    Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.

    Gertz MA

    American journal of hematology 2016; (91(9)):947-56 doi:10.1002/ajh.24433.

    PMID: 27527836
  15. 15

    Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition.

    Muchtar E, Dispenzieri A, Lacy MQ, et al.

    Annals of medicine 2017; (49(7)):545-551 doi:10.1080/07853890.2017.1304649.

    PMID: 28271734
  16. 16

    Autopsy case with concurrent transthyretin and immunoglobulin amyloidosis.

    Shintani-Domoto Y, Ishino K, Naiki H, et al.

    Pathology international 2022; (72(1)):65-71 doi:10.1111/pin.13179.

    PMID: 34637570
  17. 17

    Renal AH Amyloidosis Associated With a Truncated Immunoglobulin Heavy Chain Undetectable by Immunostaining.

    Manabe S, Hatano M, Yazaki M, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2015; (66(6)):1095-100.

    PMID: 26362695
  18. 18

    AL amyloidosis with non-amyloid forming monoclonal immunoglobulin deposition; a case mimicking AHL amyloidosis.

    Manabe S, Iwasaki C, Hatano M, et al.

    BMC nephrology 2018; (19(1)):337 doi:10.1186/s12882-018-1050-y.

    PMID: 30466387
  19. 19

    LC-MS/MS analysis of steroids in the clinical laboratory.

    Keevil BG

    Clinical biochemistry 2016; (49(13-14)):989-97.

    PMID: 27131495
  20. 20

    Cardiac Care of Patients with Cardiac Amyloidosis.

    Itzhaki Ben Zadok O, Kornowski R

    Acta haematologica 2020; (143(4)):343-351 doi:10.1159/000506919.

    PMID: 32408301
  21. 21

    Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies.

    Mangione PP, Mazza G, Gilbertson JA, et al.

    Journal of proteomics 2017; (165()):113-118 doi:10.1016/j.jprot.2017.06.016.

    PMID: 28647518
  22. 22

    Myocardial Characteristics, Cardiac Structure, and Cardiac Function in Systemic Light-Chain Amyloidosis.

    Clerc OF, Cuddy SAM, Jerosch-Herold M, et al.

    JACC. Cardiovascular imaging 2024; (17(11)):1271-1286 doi:10.1016/j.jcmg.2024.05.004.

    PMID: 39001736
  23. 23

    The clinical features and outcomes of systemic light chain amyloidosis with hepatic involvement.

    Zhao L, Ren G, Guo J, et al.

    Annals of medicine 2022; (54(1)):1226-1232 doi:10.1080/07853890.2022.2069281.

    PMID: 35481407
  24. 24

    Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.

    Hasib Sidiqi M, Gertz MA

    Blood cancer journal 2021; (11(5)):90 doi:10.1038/s41408-021-00483-7.

    PMID: 33993188

This page explains AL amyloidosis diagnostic testing and pathology terminology for educational purposes only. Always rely on your hematologist and pathologist to interpret your specific lab results and diagnostic workup.

Get notified when new evidence is published on AL amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.